Zai Lab names Liang as first CCO
Zai Lab Ltd. (NASDAQ:ZLAB) announced William Liang has joined the Chinese biotech as its first chief commercial officer. Liang has over 20 years of experience running commercial operations for pharma in China. He was previously VP of the Chinese oncology business unit at AstraZeneca plc (LSE:AZN; NYSE:AZN). Prior to that he was VP of oncology at Bristol-Myers Squibb Co. (NYSE:BMY) in China.
Liang joins Zai as the biotech prepares to launch its first product, ZL-2306. The PARP inhibitor is marketed as Zejula niraparib in the U.S. and Europe by Tesaro Inc. (NASDAQ:TSRO) to treat ovarian cancer and is in Phase III testing for breast cancer. Zai has exclusive Chinese rights, including Hong Kong and Macau, from Tesaro under a 2016 deal. ZL-2306 is under review in Hong Kong, and Zai hopes to launch the drug in 2H18...